A new strategy for antidepressant prescription

Frontiers in Neuroscience

Volumn 4, Issue NOV, 2010, Pages

  Lavergne, Francis ^a   Jay, Thérèse M ^a,b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antidepressant; Dopamine; Major depression; Prefrontal cortex; Synaptic plasticity

Indexed keywords

EID: 79960365039     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2010.00192     Document Type: Review

References (134)

1. Aan Het Rot, M, Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., and Mathew, S. J. (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139-145.
2. Ago, Y., Nakamura, S., Baba, A., and Matsuda, T. (2005). Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. Neuropsychopharmacology 30, 43-51.
3. APA (2004). DSM IV-R. Masson: APA.
4. Atkinson, J. H., Slater, M. A., Capparelli, E. V., Wallace, M. S., Zisook, S., Abramson, I., Matthews, S. C., and Garfin, S. R. (2007). Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J. Clin. Psychopharmacol. 27, 135-142.
5. Baumgartner, A., Dietzel, M., Saletu, B., Wolf, R., Campos-Barros, A., Graf, K. J., Kurten, I., and Mannsmann, U. (1993). Influence of partial sleep deprivation on the secretion of thyrotropin, thyroid hormones, growth hormone, prolactin, luteinizing hormone, follicle stimulating hormone, and estradiol in healthy young women. Psychiatry Res. 48, 153-178.
6. Berlin, I., and Lavergne, F. (1998). Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. Eur. Psychiatry 13, 138-142.
7. Bongiovanni, R., Kirkbride, B., Walmire, P., and Jaskiw, G. E. (2005). Tyrosine administration does not affect desipramine-induced dopamine levels as measured in vivo in prefrontal cortex. Brain Res. 1054, 203-206.
8. Bymaster, F. P., Zhang, W., Carter, P. A., Shaw, J., Chernet, E., Phebus, L., Wong, D. T., and Perry, K. W. (2002). Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl.) 160, 353-361.
9. Cador, M., Rivet, J. M., Kelley, A. E., Le Moal, M., and Stinus, L. (1989). Substance P, neurotensin and enkephalin injections into the ventral tegmental area: comparative study on dopamine turnover in several forebrain structures. Brain Res. 486, 357-363.
10. Carboni, E., Silvagni, A., Vacca, C., and Di Chiara, G. (2006). Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J. Neurochem. 96, 473-481.
11. Carboni, E., Tanda, G. L., Frau, R., and Di Chiara, G. (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55, 1067-1070.
12. Carlson, J. N., Visker, K. E., Nielsen, D. M., Keller, R. W. Jr., and Glick, S. D. (1996). Chronic antidepressant drug treatment reduces turning behavior and increases dopamine levels in the medial prefrontal cortex. Brain Res. 707, 122-126.
13. Caudal, D., Mailliet, F., Bergerot, D., Watilliaux, A, and Jay, T. M. (2010). "PO113.2: acute stess induces opposite changes in AMPA receptor subunits phosphorylation in prefontal cortex and amygdala," in 7th Forum of European Neuroscience (Amsterdam), 167.
14. Cerqueira, J. J., Mailliet, F., Almeida, O. F., Jay, T. M., and Sousa, N. (2007). The prefrontal cortex as a key target of the maladaptive response to stress. J. Neurosci. 27, 2781-2787.
15. Coppa-Hopman, R., Galle, J., and Pimkine, D. (2009). D1 receptor antagonist-induced long-term depression in the medial prefrontal cortex of rat, in vivo: an animal model of psychiatric hypofrontality. J. Psychopharmacol. 23, 672-685.
16. Cummings, J. L., Mackell, J., and Kaufer, D. (2008). Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimers Dement. 4, 49-60.
17. D'Aquila, P. S., Collu, M., Pani, L., Gessa, G. L., and Serra, G. (1994). Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur. J. Pharmacol. 262, 107-111.
18. Dazzi, L., Seu, E., Cherchi, G., Barbieri, P. P., Matzeu, A., and Biggio, G. (2007). Estrous cycle-dependent changes in basal and ethanol-induced activity of cortical dopaminergic neurons in the rat. Neuropsychopharmacology 32, 892-901.
19. Del Arco, A., and Mora, F. (2001). Dopamine release in the prefrontal cortex during stress is reduced by the local activation of glutamate receptors. Brain Res. Bull. 56, 125-130.
20. Delgado, P. L., Moreno, F. A., Onate, L., and Gelenberg, A. J. (2002). Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int. J. Neuropsychopharmacol. 5, 63-66.
21. Devoto, P., Flore, G., Pira, L., Longu, G., and Gessa, G. L. (2004). Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur. J. Pharmacol. 487, 105-111.
22. Ferreri, M., Lavergne, F., Berlin, I., Payan, C., and Puech, A. J. (2001). Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr. Scand. 103, 66-72.
23. Floresco, S. B., and Phillips, A. G. (2001). Delay-dependent modulation of memory retrieval by infusion of a dopamine D1 agonist into the rat medial prefrontal cortex. Behav. Brain Res. 115, 934-939.
24. Gambarana, C., Ghiglieri, O., and Graziella de Montis, M. (1995). Desensitization of the D1 dopamine receptors in rats reproduces a model of escape deficit reverted by imipramine, fluoxetine and clomipramine. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 741-755.
25. Gao, C., and Wolf, M. E. (2008). Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons. J. Neurochem. 106, 2489-2501.
26. Garattini, S. (1997). Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review. Int. Clin. Psychopharmacol. 12(Suppl. 3), S15-S19.
27. Gillin, J. C., Buchsbaum, M., Wu, J., Clark, C., and Bunney, W. Jr. (2001). Sleep deprivation as a model experimental antidepressant treatment: findings from functional brain imaging. Depress. Anxiety 14, 37-49.
28. Glue, P., Costello, M. J., Pert, A., Mele, A., and Nutt, D. J. (1990). Regional neurotransmitter responses after acute and chronic electroconvulsive shock. Psychopharmacology (Berl.) 100, 60-65.
29. Gobert, A., and Millan, M. J. (1999). Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology 21, 268-284.
30. Gobert, A., Rivet, J. M., Audinot, V., Newman-Tancredi, A., Cistarelli, L., and Millan, M. J. (1998). Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience 84, 413-429.
31. Gobert, A., Rivet, J. M., Cistarelli, J. M., and Millan, M. J. (1997a). Buspirone enhances duloxetine-and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J. Neurochem. 68, 1326-1329.
32. Gobert, A., Rivet, J. M., Cistarelli, L., and Millan, M. J. (1997b). Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J. Neurochem. 68, 1159-1163.
33. Gobert, A., Rivet, J. M., Cistarelli, L., Melon, C., and Millan, M. J. (1997c). Alpha2-adrenergic receptor blockade markedly potentiates duloxetine-and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J. Neurochem. 69, 2616-2619.
34. Gobert, A., Rivet, J. M., Cistarelli, L., Melon, C., and Millan, M. J. (1999). Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93, 1251-1262.
35. Gobert, A., Rivet, J. M., Lejeune, F., Newman-Tancredi, A., Adhumeau-Auclair, A., Nicolas, J. P., Cistarelli, L., Melon, C., and Millan, M. J. (2000). Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36, 205-221.
36. Gresch, P. J., Sved, A. F., Zigmond, M. J., and Finlay, J. M. (1995). Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem. 65, 111-116.
37. Gurden, H., Takita, M., and Jay, T. M. (2000). Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J. Neurosci. 20, RC106.
38. Gurden, H., Tassin, J. P., and Jay, T. M. (1999). Integrity of the mesocortical dopaminergic system is necessary for complete expression of in vivo hippocampal-prefrontal cortex long-term potentiation. Neuroscience 94, 1019-1027.
39. Harmer, C. J., Bhagwagar, Z., Perrett, D. I., Vollm, B. A., Cowen, P. J., and Goodwin, G. M. (2003b). Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28, 148-152.
40. Harmer, C. J., Hill, S. A., Taylor, M. J., Cowen, P. J., and Goodwin, G. M. (2003a). Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am. J. Psychiatry 160, 990-992.
41. Harmer, C. J., McTavish, S. F., Clark, L., Goodwin, G. M., and Cowen, P. J. (2001). Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacology (Berl.) 154, 105-111.
42. Heninger, G. R., Delgado, P. L., and Charney, D. S. (1996). The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29, 2-11.
43. Hesselink, M. B., De Boer, B. G., Breimer, D. D., and Danysz, W. (1999). Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm. Res. 16, 637-642.
44. Huang, M., Ichiwaka, J., Li, Z., Dai, J., and Meltzer, H. Y. (2006). Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl.) 185, 274-281.
45. Hughes, Z. A., Starr, K. R., Langmead, C. J., Hill, M., Bartoszyk, G. D., Hagan, J. J., Middlemiss, D. N., and Dawson, L. A. (2005). Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 510, 49-57.
46. Imperato, A., Puglisi-Allegra, S., Casolini, P., Zocchi, A., and Angelucci, L. (1989). Stress-induced enhancement of dopamine and acetylcholine release in limbic structures: role of corticosterone. Eur. J. Pharmacol. 165, 337-338.
47. Inoue, T., Kitaichi, Y., and Koyama, T. (2003). Treatment strategy of refractory depression and its presynaptic mechanism of action. Nihon Shinkei Seishin Yakurigaku Zasshi 23, 11-20.
48. Invernizzi, R., Pozzi, L., Vallebuona, F., Bonini, I., Sacchetti, G., and Samanin, R. (1992). Effect of amineptine on regional extracellular concentrations of dopamine and noradrenaline in the rat brain. J. Pharmacol. Exp. Ther. 262, 769-774.
49. Invernizzi, R. W., Parini, S., Sacchetti, G., Fracasso, C., Caccia, S., Annoni, K., and Samanin, R. (2001). Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex. Br. J. Pharmacol. 132, 183-188.
50. Invernizzi, R. W., Sacchetti, G., Parini, S., Acconcia, S., and Samanin, R. (2003). Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br. J. Pharmacol. 139, 1281-1288.
51. Jay, T. M. (2003). Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog. Neurobiol. 69, 375-390.
52. Jay, T. M., Gurden, H., and Yamaguchi, T. (1998). Rapid increase in PKA activity during long-term potentiation in the hippocampal afferent fibre system to the prefrontal cortex in vivo. Eur. J. Neurosci. 10, 3302-3306.
53. Jay, T. M., Rocher, C., Hotte, M., Naudon, L., Gurden, H., and Spedding, M. (2004). Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases. Neurotox. Res. 6, 233-244.
54. Jordan, S., Kramer, G. L., Zukas, P. K., Moeller, M, and Petty, F. (1994) In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18, 294-297.
55. Kan, J. P., Steinberg, R., Mouget-Goniot, C., Worms, P., and Biziere, K. (1987). SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. J. Pharmacol. Exp. Ther. 240, 251-258.
56. Kihara, T., and Ikeda, M. (1995). Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J. Pharmacol. Exp. Ther. 272, 177-183.
57. Kitaichi, Y., Inoue, T., Nakagawa, S., Izumi, T., and Koyama, T. (2004). Effect of co-administration of lithium and reboxetine on extracellular monoamine concentrations in rats. Eur. J. Pharmacol. 489, 187-191.
58. Kitaichi, Y., Inoue, T., Nakagawa, S., Izumi, T., and Koyama, T. (2005). Effect of milnacipran on extracellular monoamine concentrations in the medial prefrontal cortex of rats pre-treated with lithium. Eur. J. Pharmacol. 516, 219-226.
59. Kobayashi, A., Fujita, K., and Nakazawa, K. (1992). In rat brain amoxapine enhances dopamine metabolism: pharmacokinetic variations of the effect. Eur. J. Pharmacol. 215, 43-49.
60. Koch, S., Perry, K. W., Nelson, D. L., Conway, R. G., Threlkeld, P. G., and Bymaster, F. P. (2002). R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27, 949-959.
61. Kruse, M. S., Premont, J., Krebs, M. O., and Jay, T. M. (2009). Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex. Eur. Neuropsychopharmacol. 19, 296-304.
62. Kurata, K., Ashby, C. R. Jr., Oberlender, R., Tanii, Y., Kurachi, M., Rini, N. J., and Strecker, R. E. (1996). The characterization of the effect of locally applied N-methylquipazine, a 5-HT3 receptor agonist, on extracellular dopamine levels in the anterior medial prefrontal cortex in the rat: an in vivo microdialysis study. Synapse 24, 313-321.
63. Lakshmana, M. K., Rao, B. S., Dhingra, N. K., Ravikumar, R., Govindaiah, Sudha, S., Meti, B. L., and Raju, T. R. (1998). Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain. Neurochem. Res. 23, 1031-1037.
64. Lara-Lemus, A., Drucker-Colin, R., Mendez-Franco, J., Palomero-Rivero, M., and Perez de la Mora, M. (1998) .Biochemical effects induced by REM sleep deprivation in naive and in D-amphetamine treated rats. Neurobiology (Bp) 6, 13-22.
65. Lavergne, F., Berlin, I., Gamma, A., Stassen, H., and Angst, J. (2005). Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. Neuropsychiatr. Dis. Treat. 1, 59-68.
66. Lavergne, F., and De Mouzon, J. (2000). "Antidepressant efficacy at two weeks," in 1st ECNP Workshop (Neuropsychopharmacology E, ed), p S26. Nice, France: Elsevier.
67. Lavergne, F., and Jay, T. M. (2009). "P-29-012: a unifying theory of antidepressant action," in 9th World Congress of Biological Psychiatry (Paris: Informaworld), 385.
68. Li, S. X., Perry, K. W., and Wong, D. T. (2002). Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42, 181-190.
69. Li, Z., Huang, M., Prus, A. J., Dai, J., and Meltzer, H. Y. (2007). 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res. 1134, 70-78.
70. Linner, L., Endersz, H., Ohman, D., Bengtsson, F., Schalling, M., and Svensson, T. H. (2001). Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J. Pharmacol. Exp. Ther. 297, 540-546.
71. Lisanby, S. H., and Belmaker, R. H. (2000). Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS). Depress. Anxiety 12, 178-187.
72. Louilot, A., Mocaer, E., Simon, H., and Le Moal, M. (1990). Difference in the effects of the antidepressant tianeptine on dopaminergic metabolism in the prefrontal cortex and the nucleus accumbens of the rat. A voltammetric study. Life Sci. 47, 1083-1089.
73. Martinez-Turrillas, R., Del Rio, J., and Frechilla, D. (2007). Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem. Biophys. Res. Commun. 353, 750-755.
74. Martinez-Turrillas, R., Frechilla, D., and Del Rio, J. (2002). Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 43, 1230-1237.
75. Matsumoto, M., Shikanai, H., Togashi, H., Izumi, T., Kitta, T., Hirata, R., Yamaguchi, T., and Yoshioka, M. (2008). Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats. Brain Res. 1195, 50-55.
76. McTavish, S. F., McPherson, M. H., Harmer, C. J., Clark, L., Sharp, T., Goodwin, G. M., and Cowen, P. J. (2001). Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br. J. Psychiatry 179, 356-360.
77. Millan, M. J., Dekeyne, A., and Gobert, A. (1998). Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37, 953-955.
78. Millan, M. J., and Gobert, A. (1999). (-)-Pindolol increases dialysate concentrations of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely-moving rats. Neuropharmacology 38, 909-912.
79. Millan, M. J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J. M., and Cussac, D. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 306, 954-964.
80. Millan, M. J., Newman-Tancredi, A., Audinot, V., Cussac, D., Lejeune, F., Nicolas, J. P., Coge, F., Galizzi, J. P., Boutin, J. A., Rivet, J. M., Dekeyne, A., and Gobert, A. (2000). Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35, 79-95.
81. Mizoguchi, K., Ikeda, R., Shoji, H., Tanaka, Y., and Tabira, T. (2008a). Suppression of glucocorticoid secretion induces a behaviorally depressive state in rotarod performance in rat. Pharmacol. Biochem. Behav. 90, 730-734.
82. Mizoguchi, K., Shoji, H., Ikeda, R., Tanaka, Y., and Tabira, T. (2008b). Persistent depressive state after chronic stress in rats is accompanied by HPA axis dysregulation and reduced prefrontal dopaminergic neurotransmission. Pharmacol. Biochem. Behav. 91, 170-175.
83. Mizoguchi, K., Ishige, A., Takeda, S., Aburada, M., and Tabira, T. (2004). Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. J. Neurosci. 24, 5492-5499.
84. Mizoguchi, K., Yuzurihara, M., Nagata, M., Ishige, A., Sasaki, H., and Tabira, T. (2002). Dopamine-receptor stimulation in the prefrontal cortex ameliorates stress-induced rotarod impairment. Pharmacol. Biochem. Behav. 72, 723-728.
85. Morissette, M., and Paolo, T. D. (1996). Acute effect of 17 beta-estradiol and lithium on ovariectomized rat brain biogenic amines metabolism. J. Psychiatr. Res. 30, 95-107.
86. Muneoka, K., Shirayama, Y., Takigawa, M., and Shioda, S. (2009). Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochem. Res. 34, 542-555.
87. Nakamura, S., Ago, Y., Itoh, S., Koyama, Y., Baba, A., and Matsuda, T. (2005). Effect of zotepine on dopamine, serotonin and noradrenaline release in rat prefrontal cortex. Eur. J. Pharmacol. 528, 95-98.
88. Nakayama, K. (2002). Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 365, 102-105.
89. Nakayama, K., Sakurai, T., and Katsu, H. (2004). Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res. Bull. 63, 237-241.
90. Noda, Y., Mouri, A., Ando, Y., Waki, Y., Yamada, S. N., Yoshimi, A., Yamada, K., Ozaki, N., Wang, D., Nabeshima, T. (2010). Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int. J. Neuropsychopharmacol. 13, 1343-1354.
91. Ohnishi, T., Hayashi, T., Okabe, S., Nonaka, I., Matsuda, H., Iida, H., Imabayashi, E., Watabe, H., Miyake, Y., Ogawa, M., Teramoto, N., Ohta, Y., Ejima, N., Sawada, T., and Ugawa, Y. (2004). Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex: an [11C]raclopride positron emission tomography study in anesthetized macaque monkeys. Biol. Psychiatry 55, 484-489.
92. Owen, J. C., and Whitton, P. S. (2006). Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats. Brain Res. 1117, 206-212.
93. Pacher, P., Kohegyi, E., Kecskemeti, V., and Furst, S. (2001). Current trends in the development of new antidepressants. Curr. Med. Chem. 8, 89-100.
94. Page, M. E., and Lucki, I. (2002). Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 27, 237-247.
95. Pelton, G. H., Harper, O. L., Tabert, M. H., Sackeim, H. A., Scarmeas, N., Roose, S. P., and Devanand, D. P. (2008). Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int. J. Geriatr. Psychiatry 23, 670-676.
96. Pozzi, L., Invernizzi, R., Garavaglia, C., and Samanin, R. (1999). Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram. J. Neurochem. 73, 1051-1057.
97. Qi, H., Mailliet, F., Spedding, M., Rocher, C., Zhang, X., Delagrange, P., McEwen, B., Jay, T. M., and Svenningsson, P. (2009). Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology 56, 37-46.
98. Rabkin, J. G., Stewart, J. W., McGrath, P. J., Markowitz, J. S., Harrison, W., and Quitkin, F. M. (1987). Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatry Res. 21, 9-22.
99. Rajkumar, R., and Mahesh, R. (2010). The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J. Psychopharmacol. 24, 455-469.
100. Rivet, J. M., Gobert, L., Cistarelli, C., Melon, C., and Millan, M. J. (1998). Antidepressants (ADs) differentially modify dialysate serotonin (5HT), dopamine (DA) and noradrenaline (NAD) levels in rats. Soc. Neurosci. Abstr. 24, 440.9.
101. Rocher, C., Spedding, M., Munoz, C., and Jay, T. M. (2004). Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. Cereb. Cortex 14, 224-229.
102. Rozzini, L., Vicini Chilovi, B., Bertoletti, E., Trabucchi, M., and Padovani, A. (2007). Acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate Alzheimer's disease. Aging Clin. Exp. Res. 19, 220-223.
103. Sacchetti, G., Bonini, I., Waeterloos, G. C., and Samanin, R. (1993). Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortex. Eur. J. Pharmacol. 236, 171-175.
104. Sakaue, M., Somboonthum, P., Nishihara, B., Koyama, Y., Hashimoto, H., Baba, A., and Matsuda, T. (2000). Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br. J. Pharmacol. 129, 1028-1034.
105. Schilstrom, B., Ivanov, V. B., Wiker, C., and Svensson, T. H. (2007). Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32, 43-53.
106. Shearman, E., Rossi, S., Sershen, H., Hashim, A., and Lajtha, A. (2005). Locally administered low nicotine-induced neurotransmitter changes in areas of cognitive function. Neurochem. Res. 30, 1055-1066.
107. Shearman, E., Rossi, S., Szasz, B., Juranyi, Z., Fallon, S., Pomara, N., Sershen, H., and Lajtha, A. (2006). Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res. Bull. 69, 204-213.
108. Shoblock, J. R., Maisonneuve, I. M., and Glick, S. D. (2004). Differential interactions of desipramine with amphetamine and methamphetamine: evidence that amphetamine releases dopamine from noradrenergic neurons in the medial prefrontal cortex. Neurochem. Res. 29, 1437-1442.
109. Skolnick, P., Popik, P., and Trullas, R. (2009). Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 30, 563-569.
110. Spanagel, R., Eilbacher, B., and Wilke, R. (1994). Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat-a pharmacokinetic microdialysis study. Eur. J. Pharmacol. 262, 21-26.
111. Stassen, H. H., Angst, J., and Delini-Stula, A. (1996). Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 29, 87-96.
112. Stassen, H. H., Delini-Stula, A., and Angst, J. (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur. Neuropsychopharmacol. 3, 127-135.
113. Sun, X., Zhao, Y., and Wolf, M. E. (2005). Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J. Neurosci. 25, 7342-7351.
114. Takamori, K., Yoshida, S., and Okuyama, S. (2001). Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test. Life Sci. 69, 1919-1926.
115. Tanaka, M., Namiki, C., Thuy, D. H., Yoshida, H., Kawasaki, K., Hashikawa, K., Fukuyama, H., and Kita, T. (2004). Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. J. Neurol. Sci. 225, 135-141.
116. Tanda, G., Bassareo, V., and Di Chiara, G. (1996a). Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacology (Berl.) 123, 127-130.
117. Tanda, G., Frau, R., and Di Chiara, G. (1996b). Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology (Berl.) 127, 83-87.
118. Tanda, G., Carboni, E., Frau, R., and Di Chiara, G. (1994). Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl.) 115, 285-288.
119. Tanda, G., Frau, R., and Di Chiara, G. (1995). Local 5HT3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology (Berl.) 119, 15-19.
120. Toide, K. (1990). Effects of amantadine on dopaminergic neurons in discrete regions of the rat brain. Pharm. Res. 7, 670-672.
121. Tremblay, L. K., Naranjo, C. A., Graham, S. J., Herrmann, N., Mayberg, H. S., Hevenor, S., and Busto, U. E. (2005). Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch. Gen. Psychiatry 62, 1228-1236.
122. Tse, W. S., and Bond, A. J. (2003). Reboxetine promotes social bonding in healthy volunteers. J. Psychopharmacol. 17, 189-195.
123. Tsukada, H., Miyasato, K., Nishiyama, S., Fukumoto, D., Kakiuchi, T., and Domino, E. F. (2005). Nicotine normalizes increased prefrontal cortical dopamine D1 receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: a PET study in conscious monkeys. Neuropsychopharmacology 30, 2144-2153.
124. Ulrich, S., Northoff, G., Wurthmann, C., Partscht, G., Pester, U., Herscu, H., and Meyer, F. P. (2001). Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: a therapeutic window relationship. Pharmacopsychiatry 34, 33-40.
125. Valentini, V., Cacciapaglia, F., Frau, R., and Di Chiara, G. (2005). Selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline-rich isocortical but not prefrontal areas: dependence on serotonin-1A receptors and independence from noradrenergic innervation. J. Neurochem. 93, 371-382.
126. Valentini, V., Frau, R., and Di Chiara, G. (2004). Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J. Neurochem. 88, 917-927.
127. Wang, D., Noda, Y., Zhou, Y., Nitta, A., Furukawa, H., and Nabeshima, T. (2007a). Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission. Neuropharmacology 53, 379-389.
128. Wang, D., Noda, Y., Zhou, Y., Mouri, A., Mizoguchi, H., Nitta, A., Chen, W., and Nabeshima, T. (2007b). The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32, 1261-1271.
129. Watanabe, A. (1999). The influence of L-triiodothyronine on the action of desipramine on beta and serotonin 2A receptor, monoamines in the rat brain. Nihon Shinkei Seishin Yakurigaku Zasshi 19, 139-146.
130. Watanabe, T., Ueda, M., Saeki, Y., Hirokane, G., Morita, S., Okawa, M., Akiyama, K., and Shimoda, K. (2007). High plasma concentrations of paroxetine impede clinical response in patients with panic disorder. Ther. Drug. Monit. 29, 40-44.
131. Weikop, P., Kehr, J., and Scheel-Kruger, J. (2004). The role of alpha1-and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J. Psychopharmacol. 18, 395-403.
132. Wu, J. C., Buchsbaum, M., and Bunney, W. E. Jr. (2001). Clinical neurochemical implications of sleep deprivation's effects on the anterior cingulate of depressed responders. Neuropsychopharmacology 25, S74-S78.
133. Yoshida, K., Higuchi, H., Kamata, M., Yoshimoto, M., Shimizu, T., and Hishikawa, Y. (1998). Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 435-444.
134. Zhang, W., Perry, K. W., Wong, D. T., Potts, B. D., Bao, J., Tollefson, G. D., and Bymaster, F. P. (2000). Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23, 250-262.